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1. Introduction
1.1. The blood brain barrier
The blood brain barrier (BBB) is a selectively permeable cellular boundary between the brain
and the peripheral circulation. The principal component of the BBB is the capillary or micro‐
vessel endothelial cell (Figure 1). The endothelial cells in the brain capillaries differ from those
in the peripheral vasculature in several key features:
1. Presence of tight junctions (TJ) that limit the paracellular passage of macromolecules.
2. Restricted rate of fluid-phase endocytosis that limits the transcellular passage of macro‐
molecules [1]
3. Presence of specific transporter and carrier molecules [2]
4. Lack of fenestrations [3]
5. Increased mitochondrial content [3]
Thus, the endothelial cells of the BBB are less “leaky” than those of the peripheral vessels.
However, it has been shown that if the endothelial cells of the brain capillaries are removed
from their natural environment and allowed to vascularize the peripheral tissue, they become
more leaky [1]. In contrast, the endothelial cells from the periphery form tight junctions when
allowed to vascularize the brain parenchyma. Morphologically, the tight junctions of the BBB
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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resemble the tight junctions between epithelial cells rather than those between peripheral
vascular endothelial cells [4].
The unique tight junctions of the BBB are responsible for producing very high transendothelial
electrical resistance (TEER) of 1500 – 2000 Ωcm2 [2,5,6]. Though the microvessel endothelial
cells play a primary role in the formation of the BBB, several other cells are equally important
in maintaining the integrity of the BBB. These cells, namely, the astrocytes, pericytes, neurons
and other glial cells are said to form a “neurovascular unit” [7]. Integrity of the BBB is of utmost
importance in maintaining the homeostasis of the brain microenvironment. Disruption of the
BBB is seen in various states of inflammation (multiple sclerosis), neoplasia, infections
(meningitis, encephalitis), trauma and Alzheimer disease [8,9]. It would be highly desirable to
develop therapeutic strategies to reverse this disruption and tighten the BBB. At the same time,
a transient opening of the BBB would be advantageous for delivery of drugs into the brain in
conditions like epilepsy or Parkinson disease [2].
Figure 1. Neurovascular Unit of the blood brain barrier consists of the endothelial cells (pink) surrounded by base‐
ment membrane (gray), pericytes (yellow) and astrocyte foot processes. The tight junctions (black lines) formed be‐
tween two endothelial cells restrict the paracellular diffusion of compounds.
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1.2. Functions of the BBB
The BBB is responsible for maintaining the appropriate ionic composition of the interstitial
fluid of the brain that is required for optimum functioning of the neurons. To achieve this, the
BBB functions as a transport barrier by facilitating the uptake of the required nutrients, while
preventing the uptake of, or actively effluxing certain other molecules or toxic by-products of
metabolism [10] The BBB also functions as a metabolic barrier by virtue of possessing intracel‐
lular and extracellular enzymes. For example, extracellular enzymes such as peptidases and
nucleotidases break down peptides and ATP, respectively. Intracellular enzymes like cyto‐
chrome P450 (CYP450), primarily CYP1A and CYP2B degrade noxious substances and prevent
their entry into the brain parenchyma [10].
1.3. Role of astrocytes in the BBB
It is now known that the astrocytes play a key role in the conditioning and development of the
brain microvessel endothelial cells (BMEC). Astrocytes are one of the glial cells of the central
nervous system (CNS) that play several important roles in the structure and function of the
CNS. They are intimately associated with the BMEC such that their foot processes ensheath
99% of the external surface of the BMEC [11]. Astrocytes have been shown to alter the
properties of cocultured brain endothelial cells in the following ways [11,12].
1. Increase in barrier-related marker enzyme activities, such as that of γ-glutamyl transpep‐
tidase (GGT) and alkaline phosphatase.
2. Enhanced expression of a glucose transporter.
3. Elevation of trans-endothelial electrical resistance (TEER).
4. Tightening of the BBB as seen by decreased paracellular permeability of sucrose.
5. Increase in tight junction number, length and complexity.
It has also been shown that BMEC monolayers are less leaky if grown in the presence of
astrocyte-conditioned medium (ACM) [1,11]. The precise molecular nature of the astrocyte-
derived factors that is responsible for the tightness of the BBB have yet to be unequivocally
elucidated. However, several factors have been postulated to play a role including glial cell-
derived neurotrophic factor (GDNF), transforming growth factor-beta (TGF-β), and src-
suppressed C-kinase substrate (SSeCKS) that leads to increased angiopoietin-1 secretion. The
BMEC themselves are known to secrete factors that help in the maintenance of astrocyte health.
One such putative factor is the leukemia-inhibitory factor (LIF), a cytokine known to be
involved in astrocyte differentiation [11].
1.4. Role of pericytes in the BBB
The pericytes are specialized cells of mesenchymal lineage that have multiple organ-specific
roles. For example, they are present in the kidney as mesangial cells, in the liver as perisinu‐
soidal stellate cells and in the bone as osteoblasts [13,14]. The pericytes in the central nervous
system are closely associated with the BMEC and play an important role in the maintenance
of the BBB. Their functions include [14].
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1. Cerebrovascular autoregulation and blood flow distribution
2. Differentiation of the BBB
3. Formation and maintenance of the tight junctions of the BBB.
4. Initiation of the extrinsic (tissue factor) pathway of blood coagulation following cerebro‐
vascular injury
5. Brain angiogenesis via secretion of angiopoietin-1
6. Phagocytic and scavenging (macrophage-like) functions
7. Production of immunoregulatory cytokines like IL-1β, IL-6 and GM-CSF
8. Regulation of leukocyte transmigration, antigen presentation and T-cell activation.
2. Molecular components of the tight junctions
The tight junctions consist of both membrane proteins as well as cytoplasmic proteins [15]
(Figure 2). The integral membrane proteins are Claudins, Occludin and Junctional adhesion
molecules (JAM). There are also several cytoplasmic accessory proteins that form a plaque and
function as adapter proteins to link the membrane proteins to the actin cytoskeleton of the cell
[16,17]. These include Zonula occludens proteins (ZO-1, ZO-2, ZO-3), Cingulin, AF-6, 7H6
antigen and Symplekin. These tight junctional complexes are not static structures but rather
very dynamic entities that can “bend without breaking”, thereby maintaining structural
integrity [8].
2.1. Claudins
The  claudins  are  a  large  family  of  transmembrane  phosphoproteins  [15].  Twenty-four
members have been characterized so far,  claudins 1-24 [18,19].  Of these,  claudins 1,  3,  5
and 12  have  been  shown to  form the  tight  junctions  of  the  BBB [9,17,20,21].  Claudin-5
appears  to  be  specific  to  the  tight  junctions  of  the  endothelial  cells  and  is  called  the
“endothelial  claudin” [17].  Each claudin molecule has 4 transmembrane domains.  The
claudin on one cell binds homotypically to the claudin on the adjacent cell to form the seal
of  the  tight  junction.  The  claudins,  along  with  occludin  and  the  JAMs,  form  the  tight
Junctional strands that keep the cells together and prevent paracellular flux of macromole‐
cules from the apical to the basolateral side of polarized cells like BMEC [18]. The cytoplas‐
mic carboxy terminal of the claudins binds to the cytoplasmic ZO proteins [20]. Claudin-1
is  an  integral  component  of  the  tight  junctions  and  its  loss  is  associated  with  certain
pathologic conditions like tumours, strokes and inflammatory diseases [21].
2.2. Occludin
Occludin is  a  65-kDa transmembrane phosphoprotein  and is  distinct  from the  claudins.
However, its subcellular localization parallels that of claudins and, like the claudins, it has
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four  transmembrane  domains.  The  expression  of  occludin  is  higher  in  the  adult  BMEC
compared to the peripheral endothelial cells. However, it is not expressed in the fetal or
newborn human brain. Occludin plays an important structural, as well as a functional, role
in  the  regulation  of  BBB permeability.  As  is  the  case  with  several  other  tight  junction-
associated  proteins,  phosphorylation  or  dephosphorylation  of  serine,  threonine  or  tyro‐
sine residues on the occludin molecule is crucial for its proper functioning [17,18,22,23]. For
example, phosphorylation of occludin at serine and tyrosine residues correlates with tight
junction assembly or tightening [8].
Occludin and the claudins interact intricately on the BMEC membrane. Together, they form
channels that tightly regulate the paracellular flow of ions and other hydrophilic molecules.
Thus, they are both essential in the formation, maintenance and regulation of the BBB [16,18].
2.3. Junctional Adhesion Molecules (JAM)
These molecules play an important role in the regulation of tight junction permeability in
endothelial and epithelial cells [24]. These glycoproteins are members of the immunoglobulin
superfamily of proteins. Three different JAMs have been characterized in humans, JAM-1,
Figure 2. Schematic representation of proteins that are involved in the formation of the tight junction and adherens
junctions in brain microvessel endothelial cells.
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JAM-2 and JAM-3, also referred to as JAM-A, JAM-B and JAM-C, respectively. Besides
endothelial and epithelial cells, these molecules are also found on the surface of erythrocytes,
leukocytes and platelets and are thought to contribute to various processes like leukocyte
migration, platelet activation, angiogenesis and binding of reovirus [25]. The JAMs have short
cytoplasmic tails that interact with cytoplasmic accessory proteins like ZO-1 and may require
activation by phosphorylation, mediated by certain atypical protein kinases.
2.4. Cytoplasmic accessory proteins
Several cytoplasmic proteins appear to be essential components of the tight junctions. Among
them, the zonula occludens proteins (ZO-1, ZO-2, ZO-3) play an important role. These 3
proteins have a molecular mass of 220, 160 and 130 kDa, respectively. They belong to a family
of proteins called MAGUK (membrane-associated guanylate kinase-like protein) and form the
submembranous plaque of the tight junction [2,15]. They are structurally complex proteins
with several domains that make direct contact with claudins, occludin and JAM on one side
and the actin cytoskeleton on the other [15]. Cingulin is a double-stranded myosin-like protein
that serves as scaffolding and links the TJ accessory proteins with the cytoskeleton [8]. Actin,
the cytoskeletal protein, plays a central role in the maintenance of the TJ. Actin-degrading
macromolecules, such as cytochalasin-D, phalloidin and certain cytokines lead to disruption
of the actin cytoskeleton and hence, of the tight junctions [8].
The tight junctional proteins can be modulated by several intracellular processes that involve
calcium-signaling, phosphorylation, G-proteins, proteases and by TNF-α [4,8]. The tight
junctional complexes also help localize the proteins and lipids of the apical and basolateral cell
membranes in their respective compartments and prevent free mixing of these cell membrane
macromolecules between the two domains. Thus, the BMEC owe much of their polarity to the
TJ complexes [2,26].
3. Regulation of BBB permeability
Various factors play a role in regulating the permeability of the BBB as follows [2]:
1. Post-translational modifications of the TJ proteins. For example, phosphorylation and
dephosphorylation mediated by protein kinases and phosphatases, respectively.
2. Alteration of the actin cytoskeleton.
3. Proteolytic degradation of certain TJ components like occludin, mediated by metallopro‐
teinases.
4. In vitro models to study the BBB
In vitro models of the BBB have proven very effective to study the transport of endogenous
macromolecules like fatty acids across the BMEC. They have also been used extensively in
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pharmaceutical research to study the passage of therapeutic molecules across the BMEC [5-7].
Several studies have shown that the BMEC lose many of their special properties when removed
from their natural environment and show “dedifferentiation” behaviour. Thus, one potential
limitation of in vitro BBB models is that the BMEC may not behave as site-specific specialized
endothelial cells in vitro, but rather as common peripheral endothelial cells [7]. In spite of this
shortcoming, several successful in vitro models of the BBB have been described [27]. Many of
these have used human, bovine, and porcine or rat endothelial cells:
1. Alone [5,6,28-30], or
2. in combination with astrocyte conditioned medium supplemented with agents that
elevate intracellular cAMP [1], or
3. Co-culture of endothelial cells on one side of a filter, with astrocytes on the other [31].
5. FA transport across the BBB and effects of FA on BBB permeability
Fatty acids (FA) are key components of membranes and exhibit many biological functions in
a variety of tissues, including the key energy source for mitochondrial β-oxidation [32,33].
Cells acquire fatty acids through de novo synthesis, hydrolysis of triglycerides (TG) or uptake
from exogenous sources [33]. Minimal amount of FA are derived from TG hydrolysis and most
cells are dependent upon fatty acid uptake from the peripheral blood [32,34]. FA from the diet
are absorbed by enterocytes in the small intestine and packaged into chylomicrons as TG. The
liver also produces very low density lipoprotein (VLDL), a rich source of endogenously
generated TG. Circulating chylomicrons and VLDL particles are hydrolyzed by lipoprotein
lipase in the capillary lumen of tissues and the released FA from these lipoproteins may be
taken up by tissues in the body [35]. FA that enter into cells are then esterified and stored as
TG or transported to the mitochondria for β-oxidation. The importance of FA for the devel‐
oping and adult brain has been recently reviewed [6]. FA transport from blood into paren‐
chymal neurons is much more difficult than other cells since the tight junctions of the BBB
severely restrict passage into the brain. FA must first move via transcellular transport across
both the luminal (apical) and abluminal (basolateral) membranes of the endothelial cells and
then across the plasma membrane of the neural cells [36-38].
The mechanism of FA transport into the brain remains controversial. Several studies support
the notion that FA can move across membranes by diffusion [39,40]. Alternatively, others
studies indicate that FA may enter into cells via specific protein-mediated transport [32,41,42].
In the diffusion model, once bound to the outer membrane leaflet, they quickly reach ionization
equilibrium and the non-ionized form of fatty acids move across the membrane more rapidly
than the ionized form [43]. The main problem with the FA diffusion model has always been
whether diffusion is rapid enough to supply cells, which have a high long-chain FA metabolic
requirement with sufficient amount of FA for β-oxidation [44]. In the protein-mediated
transport model selective transport of FA occurs via specific protein transporters found on the
cell membrane [33,41,45-47]. The mechanism of FA transport into the brain and the involve‐
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ment of FA protein transporters has been reviewed [6]. We recently showed that the transport
of various FA across confluent layers of HBMEC was, in part, mediated by fatty acid transport
proteins (FATPs) [5,6]. Knock down of FATP-1 and CD36 resulted in reduced FA transport. In
addition, transport appeared to be dependent upon fatty acyl chain length and degree of
unsaturation.
The role of FA, such as arachidonic acid (AA), on BBB permeability is well documented and
controversial. Studies have indicated that a rapid influx of AA into the brain occurs upon
plasma infusion with AA [48,49]. In addition, a permeability-enhancing and neurotoxic effect
of AA has been observed [50-52]. AA is a precursor for the formation of various bioactive
molecules including prostaglandins, such as PGE2, and leukotrienes. Several studies have
indicated that the increase in BBB permeability is correlated with the formation of PGE2 [29,30,
53-56]. The prostaglandin EP2 receptor was shown to be responsible for mediating the
neuroinflammatory and neurodegenerative effects of PGE2 in a mouse model of status
epilepticus [57]. The permeability increase caused by AA in pial microvessels of rats was
effectively blocked by a combination of indomethacin (COX inhibitor) and nordihyroguaria‐
retic acid (LOX inhibitor) but not singly by either agent [58]. In that same study, AA-mediated
permeability increase was blocked by superoxide dismutase and catalase. These authors
concluded that free radicals generated by either COX or LOX pathways were responsible for
the permeability response to AA. In a mouse model of diabetic retinopathy 12-HETE and 15-
HETE, products of the lipoxygenase pathway, were shown to be responsible for increasing the
permeability of retinal endothelial cell barrier via an NADPH oxidase-dependent mechanism
[59]. Interestingly, AA inhibited the cytokine-induced up-regulation of several genes involved
in endothelial cell inflammation [60].
However, other studies have suggested that AA metabolites, such as PGE2, have a protective
role in the microvessels of the CNS and that PGE2 prevents permeability increases. For
example, the permeability increase caused by bradykinin was prevented or attenuated by
exogenously added PGE2 and iloprost, a prostacyclin analog [61]. In that study, COX-inhibitor
drugs potentiated the permeability increases caused by bradykinin, thus suggesting an
inhibitory role of PGE2 in increasing endothelial cell permeability. In addition, PGE2, acting
via EP4 receptors, inhibited the increase in BBB permeability in a mouse model of experimental
autoimmune encephalomyelitis [62]. Moreover, PGE2, acting via EP2 receptors, has neuropro‐
tective properties and limits ischemic damage in mice stroke models [63]. It has been postulated
in these studies [61,62] that engagement of EP2 and EP4 receptors by PGE2 leads to an increase
in cAMP levels. This cAMP accumulation has been shown to potentiate cadherin-mediated
cell-cell contact and enhance endothelial barrier function. Thus, PGE2 may promote BBB
integrity via direct action on endothelial cells [62].
Several studies have demonstrated that microvessel endothelial cells from various organs have
the capacity to produce a range of eicosanoids, notably, PGE2, PGI2 and PGF2α. In most of these
studies the endothelial cells were stimulated with the calcium ionophore A23187 in addition
to exogenously added AA [64-66]. However, in one study endothelial cells exposed to plasma
from preeclamptic women showed increased production of prostaglandins [67]. In addition,
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bovine brain microvessel endothelial cells (BBMEC) exposed to TNF-αreleased large amounts
of PGE2 over a 12-hour period [29].
Previous work has shown that docosahexanoic acid (DHA) is converted to its vasodilator
metabolite, 17S-HDoHE in endothelial cells [68]. DHA is a precursor in the formation of several
bioactive molecules in human blood cells and in glial cells [69]. However, in those experiments,
the cells were exposed to stimulants like zymosan A or the calcium ionophore, A23187 to
facilitate the release of DHA metabolites. These metabolites have been shown to have several
biological effects like inhibition of inflammation and platelet aggregation, mediation of
vasodilation, anti-arrhythmic effects and lowering of triglyceride levels [70].
6. Drug transport across the BBB
The tight junction complex that connects brain microvascular endothelial cells in the BBB as
well as the epithelial cells of the choroid plexus that form the blood-cerebral spinal fluid barrier
(BCSFB) serve as a physical barrier preventing the paracellular diffusion of endogenous and
exogenous compounds. The presence of these tight junctions is essential for maintaining the
proper environment required for neuronal transmission. However, paracellular diffusion of
nutrients and metabolites between the blood and the extracellular compartment of the brain
is also highly restricted. Consequently, the uptake of essential molecules, such as glucose and
amino acids, to meet the metabolic requirements of the brain occurs through specific trans‐
porter proteins located on the plasma membrane of the endothelial cells. In addition to
transporters that facilitate the entry of various solutes into the brain, the brain endothelial cells
also express numerous efflux transporters [71]. These transporters are members of the ATP-
binding cassette (ABC) protein family and utilize energy from adenosine triphosphate (ATP)
hydrolysis to actively remove compounds from the cells against a concentration gradient.
From a drug transport perspective, there are several transporters that are critically involved
in the movements of drugs across the BBB. These include organic anion-transporting poly‐
peptide 1A2 (OATP1A2/SLO1A2), organic anion transporter 3 (OAT3/SLC22A8), monocar‐
boxylate transporter 1 (MCT1/SLC16A1), from the solute transporter family, and P-
glycoprotein (P-gp; MDR1/ABCB1), breast-cancer-resistance protein (BCRP/ABCG2) and
multidrug-resistance-associated proteins 1-9(MRP1-9/ABCC1-9) from the ABC transporter
family [72]. The localization of these transporters in both the BBB and BCSF barrier are shown
in Figure 3 with each individual transporter is being discussed in greater detail below.
6.1. Organic Anion Transporting Polypeptide (OATP)
Organic anion transporting polypeptides (OATPs) are members of the solute carrier organic
anion transporter family (SLCO) [73]. The OATPs accommodate the transport of a wide variety
of amphipathic solutes, including bile salts, anionic peptides, steroid conjugates, thyroid
hormones and an increasing number of pharmaceutical drugs and xenobiotics [74]. Members
of the OATP family, of which there are currently 11 known to be expressed in humans
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(OATP1A2, 1B1, 1B3, 1C1, 2A1, 2B1, 3A1, 4A1, 4C1, 5A1, and 6A1), share a great deal of amino
acid sequence identity and transport solutes in a sodium independent manner [75].
Of the various OATPs, both OATP1A2 and OATP1A4 are expressed in the BBB. Organic anion
transport protein 1A2 was the first member of the OATP family to be reported in humans,
while OATP1A4 is a more recently discovered homolog of hepatic [76]. At the protein level,
OATP1A2 (previously designated OATP-A) is expressed in many organs including the liver,
intestine, kidney, lung, testes, and the brain. Within the brain, this transporter is localized in
the frontal cortex and specifically confined to the endothelial cells of the BBB [74]. Its locali‐
zation on the luminal side of brain microvessel endothelial cells suggests that OATP1A2 aids
in the entry of various solutes and therapeutic agents into the brain [74]. While OATP1A4 is
mainly concentrated in the liver, the transporter has also been detected within the brain
microvessel endothelial cells [74]. In contrast to OATP1A2, immunohistochemical localization
studies indicate that OATP1A4 is expressed on both the apical and basolateral side of the
endothelial cells of the BBB and thus, mediates the uptake of compounds from both the brain
and the blood compartments [77].
6.2. Organic Anion Transporter (OAT)
Organic anion transporters (OATs) belong to the SLC22A gene family. Similarly to OATPs,
the OATs transport a broad range of chemically unrelated endogenous and exogenous
compounds. There are at least 10 families of OATs designated by Arabic numbers (eg. OAT1).
Figure 3. The localization of transporters in the blood brain barrier (BBB) and blood cerebral spinal fluid barrier
(BCSFB) of CNS.
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OAT1 is predominantly expressed in the kidney although a very small amount is also found
in the brain particularly concentrated in regions such as cortex, hypothalamus, hippocampus
and cerebellum [78]. This transporter is known to interact with a broad range of drugs
including antibiotics (penicillins, benzylpenicillin and carbenicillin), antineoplastics (metho‐
trexate) and even cholesterol lowering drugs including the statins and fibrates such as
fluvastatin, pravastatin, and bezafibrate, respectively [78]. OAT2, on the other hand, is
predominantly expressed in the liver and very little is found in the kidney and brain. The
expression level of this transporter in a particular tissue can be influenced by a variety of
factors; including gender and species differences [79]. For example, in the adult male rat, the
mRNA for OAT2 expression is greater in the liver than the kidney, and the opposite is true for
the adult female rat where the mRNA level in the kidney is greater than in the liver [79].
However, this phenomenon has not been observed in humans. Furthermore, the expression
level of OAT2 is also influenced by hepatocyte nuclear factors and endogenous gas molecules
including nitric oxide [80,81]. Given the similar molecular structure to OAT1, OAT2 also
mediates the transport of a broad range of solutes including cholesterol lowering drugs (i.e.
statins), antibiotics such as cephalosporins, and antineoplastic drugs like 5-fluorouracil [78].
From a CNS perspective, OAT3 appears to have the greatest expression levels in the brain [78].
Within the CNS, OAT3 is primarily localized in the brain capillaries and in epithelial cells of
the choroid plexus, specifically on the basolateral side of the plasma membrane of the cells [82].
The predominantly basolateral localization of OAT3 in the BBB and BCSFB implies that the
primary function of OAT3 is to aid in the removal of compounds from the brain. Endogenous
products of neurotransmitter and hormone metabolism are potential candidates for OAT3-
mediated removal. Potential therapeutic agents that may be transported out of the brain
through OAT3-dependent processes at the BBB and BCSFB include the various statins,
diuretics, antibiotics and antivirals [78]. As OAT3 interacts with a large number of therapeutic
agents, drug-drug interactions may be of potential concern in the BBB, although specific
examples are at present not known.
6.3. Glucose Transporters (GLUT)
Glucose is the major source of energy for most mammalian cells, particularly in the brain.
Despite the high dependence of the brain on glycolysis, the source of glucose comes entirely
from the blood and is dependent on passage through the BBB. The entry of glucose into the
brain is mediated by facilitative glucose transporter proteins. There are currently seven known
isoforms, with the designation of GLUT1-7 [83]. The main isoforms found within the CNS are
GLUT1 and GLUT3 that bring glucose into the cell through sodium independent transport
mechanisms. A summary of the various GLUTs and their distribution within the CNS is shown
in Figure 4. GLUT1 within the CNS exists as two distinct forms, which differ only by the extent
of glycosylation [84]. A glycosylated, 55 KDa GLUT1 is found primarily in the endothelial cells
of the BBB while the non-vascular, non-glycosylated 45 KDa form is mainly found in neural
cells as well as the basolateral plasma of epithelial cells isolated from the choroid plexus [83].
Aside from the prominent expression found in the microvessels and choroid plexus, GLUT1
has also been detected in small cells with dark stained nuclei characteristic of glia cells [85].
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Immunohistochemistry staining also showed a positive detection of GLUT1 in astrocytes that
are in direct contact with the cerebral microvessels of rat brain slices. Electron microscopy also
revealed dense distribution of GLUT1 within the astrocyte foot processes surrounding the
microvessels of the gray matter and synaptic contacts [86].
Figure 4. Cellular localization of different isoforms of glucose transporter in the CNS.
The main glucose transporter in the BBB is GLUT1. This same transporter is also highly
expressed in the blood-retinal barrier, the placental barrier, and blood-CSF barrier (BCSFB)
[87-89] highlighting its importance in regulation of glucose levels in these tissues. The transport
of glucose through GLUT1 in the BBB is the rate-limiting step for glucose utilization in the
brain and is highly responsive to metabolic changes within the brain. For example, GLUT1
expression in the BBB at both the mRNA and protein level can increase or decrease depending
on the ambient concentration of hexose. High concentration of hexose decreases the expression
of GLUT1 while low hexose concentration causes an up-regulation of both GLUT1 mRNA and
protein levels [90]. Following brain injury such as a stroke and brain tumors, both mRNA and
protein levels of GLUT1 are significantly increased [83,85,91].
The endothelial cells forming the BBB also express sodium glucose cotransporter (SGLT) [92].
Unlike GLUT1, glucose transport through SGLT is sodium-dependent. A functional role for
SGLT in glucose homeostasis in the brain has not been established; however, it has been
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speculated that SGLT may help maintain intracellular glucose levels in the brain under
stressful conditions such as hypoglycemia [92].
6.4. Monocarboxylate Transporter (MCT)
Monocarboxylic acids, including lactate, pyruvate, and ketones play an important role in
energy metabolism within the body. Monocarboxylates such as pyruvate, lactate, and ketone
bodies (i.e acetoacetate and β-hydroxybutyarate) can be utilized by neurons, in the absence of
glucose, to generate a substantial amount of energy for the brain [93]. Under pathological and
physiological conditions including diabetes, prolonged starvation, hypoglycemia, or even
intense exercise, the build-up of lactate provides an energy source, which can be utilized by
the brain [3,94,95]. In addition, monocarboxylates including lactic acid are a metabolic by-
product produced and released within the CNS by neurons [96,97], astrocytes [96] and
oligodendrocytes [98]. As monocarboxylates are hydrophilic compounds that cannot readily
diffuse cross the BBB, specific transporter systems are required to maintain proper levels of
these endogenous metabolic products in the brain [93].
Sequence homology indicates that the monocarboxylate transporter family (previous known
as SLC16 gene family) consists of 14 members identified as MCT1-9, MCT11-14 and T-type
amino acid transporter 1 (TAT1) [99]. MCT1-4 is a symporter mediating the co-transport of
monocarboxylate and proton in a one to one stoichiometry ratio. MCT1-4 is present in almost
all tissues including the muscles, liver, kidney, heart, testes, and brain [93,99]. While MCT1
and MCT2 are found in the muscles, liver, kidney, heart and CNS, [93], MCT3 is exclusively
expressed on the basolateral side of the retinal pigment epithelium and MCT4 is highly
expressed in the skeletal muscles and also in the brain. Within the BBB, MCT1 was the first
monocarboxylic acid transporter identified in the brain microvessel endothelial cells and in
the ependycytes lining the ventricles [100]. Both electron microscopy and immunohistochem‐
istry revealed a small amount of MCT1 in astrocytic end-feet surrounding the capillaries
[100,101]. The presence of MCT1 was found in the cytoplasm of astrocyte and also associated
with the plasma membrane [93]. In contrast, MCT2 is found in endothelial cells forming the
BBB, but absent in astrocytes [93,100]. MCT4, on the other hand, was exclusively expressed in
the astrocytes and glial cells of rodent brain. Furthermore, when the hippocampus and the
corpus callosum were labeled, the expression of MCT4 was restricted to astrocytes [93]. MCT8
was recently recognized as thyroid hormone transporter as opposed to monocarboxylate [102].
6.5. ATP-Binding Cassette Transporters (ABC)
The ATP-binding cassette (ABC) superfamily of transporter proteins are responsible for the
active transport of a wide variety of compounds including phospholipids, ions, peptides,
steroids, polysaccharides, amino acids, organic anions, bile acids, drugs and other xenobiotic
compounds across cellular membranes. There are roughly 48 genes encoding the various
human ABC transporters, each is organized into seven subfamilies designated ABCA to ABCG
[103]. Over-expression of ABC transporters are major contributors to the development of
multidrug resistance (MDR) in cancer cells. For instance, when the MDR gene that codes for
an efflux transporter is being transfected into drug sensitive cells, the transfectant cells become
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resistant to the drugs that are substrates for the transporters resulting in a decrease in the
intracellular concentration of the drugs, thereby conferring multidrug resistance [104]. MDR
in tumor cell lines is often linked to an ATP-dependent decrease in cellular accumulation of
drugs namely through p-glycoprotein (p-gp encoded by ABCB1), multidrug resistance
proteins (MRP encoded by ABCC), and breast cancer resistance protein (BCRP encoded by
ABCG2) drug efflux transporters [105]. In addition to their function as multidrug resistance
proteins, these transporters are also expressed in normal tissue such as intestines, liver, kidney
and the BBB and BCSFB, suggesting that they also have a protective function in limiting
accumulation and distribution and speeding the elimination of xenobiotic compounds which
could result in tissue toxicity [106].
6.6. Multidrug Resistance Protein (MRP)
The multidrug resistance-associated proteins (MRPs) are a subfamily of ABC transporters.
There are currently 12 members of this subfamily designated as ABCC1-12. Of the 12, 9 have
demonstrated drug efflux transporter function and play an important role in absorption,
distribution and elimination of various drugs and metabolites. While all MRPs have the
capability to transport amphiphatic organic anions, transport substrates are not limited to
anionic species. Examples of this include the transport of nucleotide based analogs by MRP4
and MRP5, efflux of prostaglandins by MRP1, co-transport of neutral or cationic solutes as
well as glucoronide drug conjugates by MRP1 and MRP2 [107]. Within the MRPs and other
ABC transport proteins there tends to be substantial substrate affinity overlap. This is a
fascinating feature considering most members are structurally and functionally distinct from
other ABC binding cassette transporters. For example, there is only approximately 15% amino
acid sequence homology between MRPs and P-gp [108]. In addition, when comparing amino
acid sequence between different members within the MRP subfamily to MRP1, amino acid
sequence homology ranges between 33% for MRP8 and 58% for MRP3 [109].
The brain endothelial cells that form the BBB express several different MRP. Collectively the
MRP efflux transporters function to restrict the uptake and aid in the elimination of drugs,
xenobiotics and endogenous compounds from the brain. Currently, members of the MRP
family that have been reported in the BBB include MRP1, 2,4-9. The evidence for the localiza‐
tion and function of each of the MRPs within the BBB are discussed below.
6.6.1. MRP1
MRP1 is expressed in primary cultured bovine, murine [110], rat [111] and porcine [112] brain
microvessel endothelial cells. While studies by Seetharaman and coworkers [113] suggested
up-regulation of MRP1 expression in human culture brain microvessel endothelial cells
compared to freshly isolated human brain capillaries, more recent studies support robust
expression of MRP1 within the brain capillaries isolated from human brain tissue [114]. Two
independent studies reported that MRP1 is localized primarily to the apical (luminal) plasma
membrane in brain microvessel endothelial cells [114,115]. This is in contrast to studies by
Roberts et al. [116] suggesting MRP1 has a basolateral (abluminal) plasma membrane locali‐
zation in rat brain microvessels. As MRP1 shows high transporter activity for conjugated
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compounds such as estradiol 17β glucuronides [117], it is interesting to note that Sugiyama
and colleagues [118] demonstrated a reduction in elimination of estradiol 17β glucuronide
from the brain of Mrp1 knockout mice compared to that observed in the wild-type controls
with functional MRP1. These functional studies support the luminal expression of MRP1 and
suggest a role in limiting brain exposure to drugs and endogenous solutes.
6.6.2. MRP2
The expression and localization of MRP2 within the BBB is the subject of much debate. Studies
by Miller et al. [119] indicated MRP2 was expressed in the luminal plasma membrane of
isolated rat brain capillaries. These initial findings were supported by reports of MRP2
expression in both human brain capillaries as well as zebrafish [120,121]. In contrast, no
detectable expression of MRP2 was found, at either the mRNA or protein level, in bovine brain
microvessel endothelial cells [122,123] or mouse brain microvessel endothelial cells [110,118].
Furthermore, studies examining MRP2 protein expression in isolated human brain capillaries
were below detection limits [114,124]. Interestingly, expression of MRP2 in rat brain endothe‐
lial cells was inducible by activation of either pregnane X receptor (PXR) or constitutive
androstane receptor (CAR) pathways [125,126].
Functionally, MRP2 mediates the transport of glucuronide and GSH conjugates to a lesser
extent than MRP1 [127]. It also actively transports chemotherapeutics such as methotrexate,
vinca alkaloids, anthracyclins, antiepileptics such as phenytoin and endogenous agents like
leukotriene C4 [107,109,128,129]. Thus if MRP2 is expressed in the BBB, it could have a
profound effect on the brain distribution of many therapeutic agents. However, there are few
studies showing a significant impact of MRP2 on the BBB permeability. One such study
demonstrated an increased accumulation of phenytoin in the brain of Mrp2 deficient rats
compared to controls [129]. There is also evidence for MRP2-mediated changes in brain
penetration of drugs in epileptic animals. Based on available information, most evidence
indicates that MRP2 expression in the BBB is low or below detectable limits and as such has
negligible effects on solute and macromolecule distribution into the brain. However, as MRP2
expression appears highly inducible, there is a possibility that MRP2 activity in the BBB could
be of importance during pathological events within the CNS.
6.6.3. MRP3
Studies by Zhang et al. [122] identified low and variable expression of MRP3 in bovine brain
microvessel endothelial cells. Subsequent proteomics based studies of both mouse [130] and
human [131] BBB indicated that MRP3 expression was below detection limits.
6.6.4. MRP4
Evidence  supporting  a  significant  functional  role  for  MRP4  in  the  BBB  is  perhaps  the
strongest of all the MRPs. The first evidence of MRP4 expression in the BBB was the studies
by  Zhang  et  al.  [122]  in  bovine  brain  microvessel  endothelial  cells.  Follow-up  studies
examining the localization of MRP4 suggested both luminal and abluminal presence of the
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transporter [115]. The expression of MRP4 has since been reported in human, mouse and
rat BBB [114,116,132]. Comparison of MRP4 expression in the brains of wild-type and Mrp4
knockout  mice  confirmed  BBB  localization  as  well  as  expression  in  the  choroid  plexus
epithelial cells forming the BCSFB [132].
Functionally, MRP4 can transport a wide variety of substrates and is important in the efflux
of many nucleotide analog based chemotherapeutics. As with MRP1 and MRP2, MRP4
transports the endogenous substrate leukotriene C4 [133,134]. However, in addition, MRP4
can also transport endogenous nucleotides such as cAMP and cGMP [135]. Common chemo‐
therapeutic purine nucleotide anion analogs that are effluxed by this transporter include
bis(pivaloyloxymethyl)-9-[2-(phosphonomethoxy)ethyl]-adenine (PMEA), and active metab‐
olites of 6-mercaptopurine and 6-thioguanine [72,107,136]. Using Mrp4 -/- knockout mice
significant increases in topotecan [132] and PMEA [137] accumulation in the brain was
observed.
6.6.5. MRP5 and MRP6
Within the BBB, MRP5 is highly expressed, whereas MRP6 is expressed to a lesser extent [122].
Presently their locations within the BBB remain unclear. Previous studies by Zhang et al. [115]
found MRP5 protein expression to be primarily in the apical membrane fraction of brain
microvessel endothelial cells. These findings were supported by Nies et al. [114]. In contrast,
Roberts et al. [116] found low levels of abluminal MRP5 expression when staining in rat brain
microvessel endothelial cells. Currently, the location of MRP6 remains to be seen because no
specific MRP6 antibody is available at this time [115].
MRP5 can transport purine nucleotide analogs [127] and is the primary active transporter of
cGMP and cAMP [138]. Therefore MRP5 and -4 may work in concert to regulate cGMP and
cAMP levels [127] in the brain. MRP6 can transport anionic organic ions but cannot transport
glucuronide or GSH [127] and has been shown to transport leukotrinene C4 [139].
6.6.6. MRP7, -8 and -9
Currently, little is known about these transporters with regards to the BBB. MRP7, -8 and -9
have been found to be expressed in brain [140]. MRP7 can transport glucuronide E2 17betaG
and exhibits high levels of resistance to taxane docetaxel, approximately 9 to 13 fold [140].
MRP8 is able to transport nucleotide analogues such as PMEA, glutathione conjugates and
methotrexate [140]. No substrates for MRP9 have been identified at this time [109].
When looking at drug resistant efflux transport in the literature, major focus has been put on
P-gp and BCRP and limited research has been focused on members within the MRP subfamily
as it relates to the BBB. As has been demonstrated here, many of these MRP transporters can
transport substrates that are important both physiologically and in the clinic. Particularly
within the CNS, it is important to decipher any discrepancies in location and expression of
MRP members within the BBB because they can have relevant impact on CNS drug concen‐
trations reaching therapeutic levels within the brain and thus can affect our ability to treat
important brain pathologies.
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6.7. Breast Cancer Resistance Protein (BCRP)
BCRP was originally discovered in the MCF-7 AdrVp breast cancer cell line after observing
that the cells are resistant to chemotherapeutic drugs including mitoxantrone, doxorubicin,
and daunorubicin [141]. The gene sequence of the protein was isolated shortly after and was
classified as the group G subfamily of ABC transporters. There are at least 5 members of ABCG
subfamily identified in humans (ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8). However,
the primary form that plays a crucial role in the transport of substances between the blood and
the CNS is ABCG2 [141]. At the protein level, ABCG2 is approximately 72-kDa with 665 amino
acids and is considered as a half-transporter as shown in Figure 5. Other ABC transporters
have two sets of membrane spanning regions (6 transmembrane α-helices) and two nucleotide
binding domains (NBD); the G subfamily of protein consists of only one set of membrane
spanning domain 6 transmembrane α-helices and only one NBD [141]. In order to function, it
is believed that these half-transporters form homodimers [142].
The specific localization of ABCG2 within the CNS is primarily confined to the luminal plasma
membrane of the brain microvessel endothelial cells. Given the localization within the BBB
and the compounds that are transported by ABCG2, it has been suggested that ABCG2 most
likely protects the brain from xenobiotics and toxins similar to other ABC transporters [141].
Furthermore, ABCG2 also plays a role in the accumulation and disposition of various endog‐
enous substrates including sulfate and glucuronide conjugates of estrone and dehydroepian‐
drosterone [143,144]. In addition to endogenous substrates, ABCG2 also binds and recognizes
a broad range of structurally-unrelated drugs and xenobiotics [141]. Many of these transport
substrates also interact with other ABC transporters including ABCB1 and the ABCC subfam‐
ily; thus, the accumulation and distribution of drugs can be significantly altered.
6.8. P-glycoprotein (P-gp)
P-glycoprotein (P-gp) was the first ABC transporter to be characterized. First identified by
Juliano and Ling [145] in 1976 using Chinese hamster ovary cells with selected resistance to
colchicine, they discovered that the drug resistance properties of the mutated cells were
consistently correlated with a high molecular weight component found in the plasma mem‐
brane with an approximate weight of 170,000 Da [145]. They also observed that the component
was likely a glycoprotein associated with the plasma membrane of the mutated cells and was
consistently absent or expressed at a lower level in the wild-type cells. Furthermore, they also
noticed that the mutant cells with high levels of glycoprotein displayed an alter drug perme‐
ability; thus, they designated it as “P-glycoprotein” [145]. P-gp is also expressed in numerous
tissues, including adrenal glands, kidneys, liver, colon, small intestine, heart, testes, peripheral
nerves, and the brain. At the BBB, it is the most extensively studied ABC transporter being
expressed in the luminal plasma membrane of brain endothelial cells [104]. Under normal
conditions, the presence of P-gp in the BBB limits a broad range of substances from penetrating
the brain tissue. Some notable drug classes with reduced brain penetration due to P-gp efflux
at the BBB include anti-epileptics, anti-cancer drugs, anti-histamines and HIV protease
inhibitors [103]. Numerous studies using drugs such as cyclosporine, digoxin, domperidone,
etoposide, loperamide, ondansetron, taxol and vinblastine have shown the important role of
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P-gp in the pharmacokinetics of P-gp substrates in multiple parts of the body. Table 1 shows
some of the drugs that are known substrates for P-gp.
Similar to other ABC transporters, P-gp is a transmembrane protein with a molecular weight
of 170 KDa formed by two homologous subunits that function as an efflux pump in an ATP-
dependent manner (shown in Figure 5). The protein is assembled in two halves connected by
Figure 5. Structures of (A) MRP transporter, (B) BCRP transporter, and (C) P-glycoprotein transporter.
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a 75 amino acid linker region. Each half contains 6 transmembrane segments, an intracellular
nucleotide binding domain, and both intracellular N and C terminal regions. The exact
localization of P-gp had been a subject of some debate with evidence supporting both luminal
and abluminal expression of the protein. Luminal P-gp expression had been observed in rat
and mouse brain capillaries [115,146,147]. Furthermore, the luminal expression of P-gp has
also been isolated in human brain microvessels [113,148]. In contrast, electron microscope
techniques have shown an enhanced expression of P-gp on the abluminal side of the rat brain
endothelial cells [149]. Nevertheless, recent studies using immunoreactivity support the
localization of P-gp on the luminal side of the endothelial cells [116].
Table 1 Representative compounds that are known to be P-glycoprotein substrates. (Adapted from [156] )
Numerous studies have attempted to identify and characterize P-gp substrates. Unlike
conventional transporters, which recognize specific substrates, P-gp recognizes a broad range
of compounds and has the capacity to extract its substrates directly from the plasma membrane
[150]. Some of the most common features of P-gp substrates include their lipophilic nature that
enables them to cross the lipid bilayer of the cell membrane. Furthermore, many P-gp sub‐
strates commonly consist of two aromatic rings and a basic nitrogen atom. These molecules
can be uncharged or basic in nature, although some acidic compounds including methotrexate
and phenytoin can also bind to P-gp but at a lower rate. Molecules with molecular weight
ranges from 300 to 2000 Da are capable of binding to the protein and being transported [151].
Peptide substrates consisting of 3 to 15 amino acids with molecular weight ranges from 380 to
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1880 Da can also interact with P-gp [151]. Most recently, beta amyloid protein, the component
found in amyloid plaques in Alzheimer’s disease was reported to be a transport substrate of
both P-gp but not BCRP [152,153].
One method for overcoming the limited permeability of P-gp transport substrates is to
pharmacologically inhibit Pgp. P-glycoprotein inhibitors are themselves non-cytotoxic agents
that can be used in combination with P-gp substrates to maintain the intracellular drug
concentration. An inhibitor binds to P-gp and prevents the transport of P-gp substrates. There
are at least three generations of P-gp inhibitors. The first generation compounds are less potent
and non-selective with undesirable side effects at inhibitory concentrations. Examples of first
generation inhibitors include the calcium channel blocker, verapamil, and the immunosup‐
pressive agent cyclosporin A. First generation P-gp inhibitors act as competitive inhibitors of
P-gp transport [154].
The second-generation compounds including dexverapamil or dexniguldipine were devel‐
oped to reduce the toxicity associated with P-gp inhibition. They eliminate the undesirable
side effects while retaining the ability to inhibit P-gp. The third generation inhibitors including
tariquidar and elacridar are much more specific and more potent than earlier compounds.
Unlike the first and second generation of P-gp inhibitors, the third generation of drugs acts as
non-competitive inhibitors of P-gp, and the compounds themselves are not transported by P-
gp [155]. Table 2 summarizes representative P-gp inhibitors [104].
Table 2 Representative compounds that are known to be P-glycoprotein inhibitors. (Adapted from [156] )
The ability of P-gp to extrude xenobiotics provides protection and detoxification of cells under
normal conditions. For example, knockout mice (MDR1a-/-) have been shown to be more
sensitive to ivermectin and are susceptible to serious neurotoxicity compared to wild type
control mice [156]. Considering the broad range of P-gp substrates and the expression of P-gp
in tissues responsible for absorption, distribution and elimination of drugs, it is no surprise
that this particular drug efflux transporter can significantly affect the absorption and distri‐
bution of drugs. This is especially true for cancer therapies used in the treatment of brain
tumors. The tight junctions of the BBB restrict paracellular diffusion of chemotherapeutic
agents into the CNS, while the presence of the various drug efflux transporters, such as P-gp,
within the endothelial cells of the BBB reduces transcellular passage of chemotherapeutic
agents into the brain and tumor sites.
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7. Conclusion
The brain capillaries are structurally and functionally different from capillaries formed in the
other organs. The selectiveness and permissiveness of the endothelial cell monolayer within
the CNS is dependent on the tight junctions as wells as the numerous transporter systems
located on the luminal and the abluminal surface of the endothelial cells forming the BBB. The
restrictive nature of the tight junctions along with transporter systems expressed in the BBB
can significantly altered the accumulation and distribution of fatty acids and drugs in the CNS
under pathological conditions. Improved delivery to the brain can be achieved by reversibly
disrupting the physical tight junctions and/or inhibiting the activity of efflux transporter
systems.
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